Lack of indinavir-associated nephrological complications in HIV-infected adults (Predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire

AIDS Research and Human Retroviruses

Volumn 23, Issue 1, 2007, Pages 62-66

  Danel, Christine ^a   Moh, Raoul ^a   Peytavin, Gilles ^b   Anzian, Amani ^a   Minga, Albert ^a   Gomis, Olivier Ba ^a   Seri, Boga ^a   Nzunettu, Gustave ^a,c   Gabillard, Delphine ^d   Salamon, Roger ^d   Bissagnene, Emmanuel ^c   Anglaret, Xavier ^d  

^a Programme PAC CI   (Côte d’Ivoire)

^b BICHAT HOSPITAL   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; COTE D'IVOIRE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RACE DIFFERENCE; STANDARD; TREATMENT DURATION; VIRUS LOAD;

ADULT; COHORT STUDIES; COTE D'IVOIRE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; INDINAVIR; MALE; RETROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33846821901     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0038     Document Type: Article

References (30)

1. Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, and Deutsch PJ: Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 2001;45:2710-2715.
2. Bucher HC, Bichsel M, Taffe P, et al.: Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: The Swiss HIV Cohort Study. HIV Med 2002;3:247-253.
3. Aarnoutse RE, Wasmuth JC, Fatkenheuer G, et al.: Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antiviral Ther 2003;8:309-314.
4. Hirsch MS, Brun-Vezinet F, Clotet B, et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128.
5. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-8276.
6. Danel C, Moh R, Minga A, et al.: Failure of a CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults: a randomized trial in West Africa (Trivacan ANRS1269 Trial). Lancet 2006;36:1981-1989.
7. Moh R, Danel C, Sorho S, et al.: Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire. Antiviral Ther 2005;10:615-625.
8. Anglaret X, Dakoury-Dogbo N, Bonard D, et al.: Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Côte d'Ivoire. AIDS 2002;16:909-918.
9. Rouet F, Ekouevi D, Chaix M, et al.: Real-time PCR test for human immunodeficiency virus type-1 infection in an African resource-limited setting. J Clin Microbiol 2005;43:2709-2717.
10. Good SS, Reynolds DJ, and de Miranda P: Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr 1988;431:123-133.
11. Woolf E, Au T, Haddix H, and Matuszewski B: Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A 1995;692:45-52.
12. Drew RH, Weller S, Gallis HA, Walmer KA, Bartlett JA, and Blum MR: Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1989;33:1801-1803.
13. Voigt E, Wickesberg A, Wasmuth JC, et al.: First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med 2002;3:277-282.
14. Konopnicki D, De Wit S, Poll B, Crommentuyn K, Huitema A, and Clumeck N: Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: Comparison of 800/100 mg and 400/100 mg twice daily. HIV Med 2005;6:1-6.
15. Acosta EP, Wu H, Hammer SM, et al.: Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr 2004;37:1358-1366.
16. min is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002;29:374-377.
17. Burger DM, Hugen PW, Aarnoutse RE, et al.: A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: Pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001;26:218-224.
18. Arnaiz JA, Mallolas J, Podzamczer D, et al.: Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003;17:831-840.
19. Burger D, Boyd M, Duncombe C, et al.: Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003;51:1231-1238.
20. Duval X, Peytavin G, Albeit I, et al.: Determination of indinavir and nelfmavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med 2004;5:307-313.
21. Herman JS, Ives NJ, Nelson M, Gazzard BG, and Easterbrook PJ: Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001;48:355-360.
22. Dieleman JP, Sturkenboom MC, Jambroes M, et al.: Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: The ATHENA cohort. Arch Intern Med 2002;162:1493-1501.
23. Balani SK, Woolf EJ, Hoagland VL, et al.: Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996;24:1389-1394.
24. Mortier E, Toure S, Seyler C, Bloch M, and Anglaret X: Urinary pH in HIV-infected adults in Ivory Coast and in France. AIDS 2003;17:2003-2005.
25. Kappelhoff BS, Huitema AD, Sankatsing SU, et al.: Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005;60:276-286.
26. Lin JH, Chiba M, Chen IW, Nishime JA, and Vastag KS: Sex-dependent pharmacokinetics of indinavir: In vivo and in vitro evidence. Drug Metab Dispos 1996;24:1298-1306.
27. Gagnon RF, Tecimer SN, Watters AK, and Tsoukas CM: Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000;36:507-515.
28. Dworkin MS and Wan PT: Indinavir, zidovudine, lamivudine: 3-year follow-up. Ann Intern Med 2001;134:165.
29. Ghosn J, Lamotte C, Ait-Mohand H, et al.: Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003;17:209-214.
30. Duvivier C, Myrto A, Marcelin AG, et al.: Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antiviral Ther 2003;8:603-609.